A Study of Tongue Strength and Endurance Using the Iowa Oral Performance Instrument (IOPI) Tongue Strength Trainer in People With Oral Tongue Cance
Launched by MEMORIAL SLOAN KETTERING CANCER CENTER · Aug 8, 2025
Trial Information
Current as of September 09, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying tongue strength and how long the tongue can hold pressure in people with tongue cancer. Researchers are using a special device called the Iowa Oral Performance Instrument (IOPI) to measure how strong the tongue is by checking the pressure it can create. The goal is to better understand tongue function in people who are preparing for surgery to remove part of their tongue due to cancer.
People who might be eligible for this study are adults 18 years and older who are scheduled to have surgery to remove part of their tongue because of cancer. The surgery can be one of several types, but it should not involve removing large parts of the tongue or jawbone. People who have had previous radiation or surgery for mouth or head and neck cancer, or who rely on feeding tubes before surgery, cannot join. If you take part, you will have your tongue strength tested with the IOPI device before and after surgery. This study is currently looking for participants, and it includes both men and women between the ages of 65 and 74.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age ≥18 years old
- • Scheduled to undergo primary surgery for oral tongue cancer (glossectomy types 1 to 3) using any type of closure or reconstruction
- Exclusion Criteria:
- • Previous radiation therapy to the oral cavity or head and neck
- • Previous surgery for oral cavity cancer
- • Recurrent oral cavity cancer
- • Surgical requirement of extension to involve bone (mandible resection)
- • Subtotal or total glossectomy
- • Feeding tube dependance prior to surgery
About Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center (MSKCC) is a world-renowned institution dedicated to cancer treatment, research, and education. As a leading clinical trial sponsor, MSKCC focuses on advancing innovative cancer therapies through rigorous scientific investigation and collaboration. The center's multidisciplinary team of experts employs cutting-edge methodologies to design and conduct trials that aim to improve patient outcomes and enhance understanding of cancer biology. With a commitment to translating research findings into clinical practice, MSKCC plays a pivotal role in shaping the future of oncology care and ensuring that patients have access to the latest therapeutic advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Middletown, New Jersey, United States
Montvale, New Jersey, United States
Harrison, New York, United States
Basking Ridge, New Jersey, United States
Commack, New York, United States
Uniondale, New York, United States
New York, New York, United States
Patients applied
Trial Officials
Louise Cunningham
Principal Investigator
Memorial Sloan Kettering Cancer Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported